生物制药公司Genmab （GMAB） 据悉已进入收购荷兰癌症药物开发商Merus （NASDAQ：MRUS） 的深入谈判阶段。今年市值增长60%的Merus预计很快将宣布并购协议。此次收购将增强Genmab的肿瘤产品组合，尽管仍可能出现其他竞标者。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：张俊 SF065

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.